Abstract：【Objective】To investigate the effect of gemcitabine combined with oxaliplatin in the treatment of recurrent refractory non-hodgkin's lymphoma (NHL). 【Methods】The clinical data of 86 patients with relapsed refractory NHL in our hospital from July 2015 to July 2018 were retrospectively analyzed. According to the treatment methods, the control group (43 cases) was treated with vinorelbine combined with oxaliplatin, while the observation group (43 cases) was treated with gemcitabine combined with oxaliplatin. The therapeutic effects of the two groups were compared. 【Results】The clinical effective rate of the observation group was 72.09% (31/43), which was higher than that of the control group (62.79%, 27/43). However, the difference was not statistically significant (χ2= 0.847, P=0.357).After treatment, the KPS scores of the two groups were both higher than corresponding KPS scores before treatment (P<0.05), while the difference of post-treatment between the control group and the observation group was not statistically significant (P>0.05).The incidence of thrombocytopenia, gastrointestinal reactions and peripheral nerve symptoms in the observation group was lower than that in the control group (P<0.05).After 12 months of follow-up, the progression-free survival rate and overall survival rate were 58.14% and 81.40% in the study group,respectively. If they were compared to the progression-free survival rate (55.81%) and overall survival rate (76.74%) in the control group, the difference was not statistically significant (χ2=0.047, P=0.827; χ2=0.281, P=0.596). 【Conclusion】Combined use of gemcitabine and oxaliplatin in the treatment of relapsed and refractory NHL has the same effect as vinorelbine combined with oxaliplatin.
阿孜古丽, 毛敏, 木合拜尔·阿布都尔, 安利. 吉西他滨联合奥沙利铂治疗复发或难治性NHL的临床疗效[J]. 医学临床研究, 2021, 38(12): 1826-1828.
Aziguli, MAO Min, Muhebaier·Abuduer, et al. Effect Analysis of Gemcitabine Combined with Oxaliplatin in the Treatment of Relapsed or Refractory NHL. JOURNAL OF CLINICAL RESEARCH, 2021, 38(12): 1826-1828.
2021, Vol. 38 
